Mr. John Hennessy:

We know there is more and we are anxious to get there. However, the success in the area of generics was due to the enabling legislation that allowed substitution, which is not there for biosimilars. That relies on prescriber behaviour, which is an influencing factor rather than a directing matter. It would be interesting to have legislation on that to enable it to happen more quickly but altering prescribing behaviour is a slow process.